A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...

Two years after percutaneous coronary intervention, people at risk of a cardiac event had better outcomes with clopidogrel ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having excessive bleeding in the months following the procedure. While routine ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open ...

A step forward in de-escalating treatment The evolution of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has been shaped by the continuous challenge of balancing ...

A Stanford University study presented at the American College of Cardiology’s annual session finds no significant differences ...

Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with ...

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, experienced significantly better outcomes with clopidogrel ...